← All organizations

Assertio

For profitWebsite ↗

Also known as: ASSERTIO | DepoMed | DEPOMED INC | DEPO NF | OTTER PHARMS | Sponsor/Depomed, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

Last known activity

Nov 1, 2018

Timeline

1990s

Jun 1, 1995
Assertio— Founded

2010s

Jan 28, 2011
gabapentin— NDA Secondary Org
Jan 1, 2012
Xanodyne Pharmaceuticals— Acquired
Nov 1, 2018
clobazam— Marketing Organization

2020s

May 15, 2020
Zyla Life Sciences— Acquired

Drugs by trial phase (19 distinct, 43 trials)

Phase 4 (3 own, 3 via acquisition)

Phase 3 (1 own, 2 via acquisition)

Phase 2 (3 own, 2 via acquisition)

Phase 1 (0 own, 5 via acquisition)

Indications

Studied for

Marketed drugs (6)

Subsidiaries (2 direct, 2 total across the full acquisition tree)

Recent trials (26)

NCT02664116CollaboratorPhase 4Jan 1, 2016
NCT03179345Lead sponsorPhase 4Sep 24, 2015
NCT03179345Study directorPhase 4Sep 24, 2015
NCT02571634CollaboratorPhase 4May 1, 2015
NCT02081391CollaboratorPhase 3Jan 1, 2015
NCT02287376Lead sponsorPhase 4Jan 1, 2015
NCT02470390Study directorPhase 4Nov 1, 2014
NCT02470390Lead sponsorPhase 4Nov 1, 2014
NCT02221674CollaboratorPhase 2Nov 1, 2014
NCT02287350Lead sponsorPhase 4Sep 1, 2014
NCT01982539Lead sponsorPhase 4Nov 1, 2013
NCT01832402CollaboratorPhase 2Jun 1, 2013
NCT01756651CollaboratorPhase 1Feb 1, 2013
NCT02052414CollaboratorN/AJul 1, 2012
NCT01515410Study directorPhase 2Jan 1, 2012

Details

Founded: Newark, CA, US Jun 1, 1995
Last known activity: Nov 1, 2018